Literature DB >> 26002743

Distribution and Cellular Uptake of PEGylated Polymeric Particles in the Lung Towards Cell-Specific Targeted Delivery.

Tammy W Shen1, Catherine A Fromen2, Marc P Kai2, J Christopher Luft1, Tojan B Rahhal1, Gregory R Robbins3, Joseph M DeSimone4,5,6,7.   

Abstract

PURPOSE: We evaluated the role of a poly(ethylene glycol) (PEG) surface coating to increase residence times and alter the cellular fate of nano- and microparticles delivered to the lung.
METHODS: Three sizes of PRINT hydrogel particles (80 × 320 nm, 1.5 and 6 μm donuts) with and without a surface PEG coating were instilled in the airways of C57/b6 mice. At time points of 1, 7, and 28 days, BALF and whole lungs were evaluated for the inflammatory cytokine Il-6 and chemokine MIP-2, histopathology, cellular populations of macrophages, dendritic cells (DCs), and granulocytes, and particulate uptake within these cells through flow cytometry, ELISAs, and fluorescent imaging.
RESULTS: Particles of all sizes and surface chemistries were readily observed in the lung with minimal inflammatory response at all time points. Surface modification with PEGylation was found to significantly increase lung residence times and homogeneous lung distribution, delaying macrophage clearance of all sizes, with the largest increase in residence time observed for 80 × 320 nm particles. Additionally, it was observed that DCs were recruited to the airway following administration of unPEGylated particles and preferentially associated with these particles.
CONCLUSIONS: Pulmonary drug delivery vehicles designed with a PEG surface coating can be used to delay particle uptake and promote cell-specific targeting of therapeutics.

Entities:  

Keywords:  Microparticle; Nanoparticle; PEGylation; Pulmonary drug delivery

Mesh:

Substances:

Year:  2015        PMID: 26002743      PMCID: PMC4580499          DOI: 10.1007/s11095-015-1701-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  48 in total

Review 1.  Targeting to macrophages: role of physicochemical properties of particulate carriers--liposomes and microspheres--on the phagocytosis by macrophages.

Authors:  Fakhrul Ahsan; Isabel P Rivas; Mansoor A Khan; Ana I Torres Suarez
Journal:  J Control Release       Date:  2002-02-19       Impact factor: 9.776

2.  Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules.

Authors:  Catherine Lombry; David A Edwards; Véronique Préat; Rita Vanbever
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-12-24       Impact factor: 5.464

3.  Role of particle size in phagocytosis of polymeric microspheres.

Authors:  Julie A Champion; Amanda Walker; Samir Mitragotri
Journal:  Pharm Res       Date:  2008-03-29       Impact factor: 4.200

Review 4.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

Authors:  Donald E Owens; Nicholas A Peppas
Journal:  Int J Pharm       Date:  2005-11-21       Impact factor: 5.875

5.  PEGylation of antibody fragments greatly increases their local residence time following delivery to the respiratory tract.

Authors:  Salome Juliette Koussoroplis; Geneviève Paulissen; Donatienne Tyteca; Hadi Goldansaz; Julie Todoroff; Céline Barilly; Catherine Uyttenhove; Jacques Van Snick; Didier Cataldo; Rita Vanbever
Journal:  J Control Release       Date:  2014-05-17       Impact factor: 9.776

6.  PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin.

Authors:  Brijeshkumar Patel; Vivek Gupta; Fakhrul Ahsan
Journal:  J Control Release       Date:  2012-07-16       Impact factor: 9.776

7.  Lung gene therapy with highly compacted DNA nanoparticles that overcome the mucus barrier.

Authors:  Jung Soo Suk; Anthony J Kim; Kanika Trehan; Craig S Schneider; Liudmila Cebotaru; Owen M Woodward; Nicholas J Boylan; Michael P Boyle; Samuel K Lai; William B Guggino; Justin Hanes
Journal:  J Control Release       Date:  2014-01-14       Impact factor: 9.776

8.  Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis.

Authors:  R Sharma; D Saxena; A K Dwivedi; A Misra
Journal:  Pharm Res       Date:  2001-10       Impact factor: 4.200

9.  Acute inflammatory responses in the airways and peripheral blood after short-term exposure to diesel exhaust in healthy human volunteers.

Authors:  S Salvi; A Blomberg; B Rudell; F Kelly; T Sandström; S T Holgate; A Frew
Journal:  Am J Respir Crit Care Med       Date:  1999-03       Impact factor: 21.405

Review 10.  Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles.

Authors:  Günter Oberdörster; Eva Oberdörster; Jan Oberdörster
Journal:  Environ Health Perspect       Date:  2005-07       Impact factor: 9.031

View more
  11 in total

1.  Nanoparticles size-dependently initiate self-limiting NETosis-driven inflammation.

Authors:  Luis E Muñoz; Rostyslav Bilyy; Mona H C Biermann; Deborah Kienhöfer; Christian Maueröder; Jonas Hahn; Jan M Brauner; Daniela Weidner; Jin Chen; Marina Scharin-Mehlmann; Christina Janko; Ralf P Friedrich; Dirk Mielenz; Tetiana Dumych; Maxim D Lootsik; Christine Schauer; Georg Schett; Markus Hoffmann; Yi Zhao; Martin Herrmann
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

Review 2.  Polymeric nanoparticles in development for treatment of pulmonary infectious diseases.

Authors:  Young H Lim; Kristin M Tiemann; David A Hunstad; Mahmoud Elsabahy; Karen L Wooley
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2016-03-25

3.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

4.  Evaluating UiO-66 Metal-Organic Framework Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications.

Authors:  Bader M Jarai; Zachary Stillman; Lucas Attia; Gerald E Decker; Eric D Bloch; Catherine A Fromen
Journal:  ACS Appl Mater Interfaces       Date:  2020-08-20       Impact factor: 9.229

5.  Neutrophil-Particle Interactions in Blood Circulation Drive Particle Clearance and Alter Neutrophil Responses in Acute Inflammation.

Authors:  Catherine A Fromen; William J Kelley; Margaret B Fish; Reheman Adili; Jeffery Noble; Mark J Hoenerhoff; Michael Holinstat; Omolola Eniola-Adefeso
Journal:  ACS Nano       Date:  2017-10-19       Impact factor: 15.881

Review 6.  Nanotherapeutics in the treatment of acute respiratory distress syndrome.

Authors:  Pragya Prasanna; Shweta Rathee; Arun Upadhyay; Sulakshana Sulakshana
Journal:  Life Sci       Date:  2021-03-27       Impact factor: 6.780

7.  Nanoparticle surface charge impacts distribution, uptake and lymph node trafficking by pulmonary antigen-presenting cells.

Authors:  Catherine A Fromen; Tojan B Rahhal; Gregory R Robbins; Marc P Kai; Tammy W Shen; J Christopher Luft; Joseph M DeSimone
Journal:  Nanomedicine       Date:  2015-12-01       Impact factor: 5.307

Review 8.  Nanoparticle Delivery Systems with Cell-Specific Targeting for Pulmonary Diseases.

Authors:  Zicheng Deng; Gregory T Kalin; Donglu Shi; Vladimir V Kalinichenko
Journal:  Am J Respir Cell Mol Biol       Date:  2021-03       Impact factor: 6.914

Review 9.  Use of nanotechnology in combating coronavirus.

Authors:  Saee Gharpure; Balaprasad Ankamwar
Journal:  3 Biotech       Date:  2021-06-28       Impact factor: 2.406

10.  Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine.

Authors:  Hadi Ghaffari; Ahmad Tavakoli; Abdolvahab Moradi; Alijan Tabarraei; Farah Bokharaei-Salim; Masoumeh Zahmatkeshan; Mohammad Farahmand; Davod Javanmard; Seyed Jalal Kiani; Maryam Esghaei; Vahid Pirhajati-Mahabadi; Seyed Hamidreza Monavari; Angila Ataei-Pirkooh
Journal:  J Biomed Sci       Date:  2019-09-10       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.